-
Views
-
Cite
Cite
News and Reviews, The Journal of Clinical Endocrinology & Metabolism, Volume 99, Issue 8, 1 August 2014, Pages 23A–24A, https://doi.org/10.1210/jc.2014-v99i8-23A
- Share Icon Share
Extract
IN PREMENOPAUSAL WOMEN WITH HORMONE-RECEPTOR–POSITIVE early breast cancer, treatment with exemestane plus ovarian suppression significantly reduces recurrence versus treatment with tamoxifen plus ovarian suppression.
(NEJM [July 10, 2014] 371:107)
SIMVASTATIN AT A DAILY DOSE OF 40 mg does not affect exacerbation rates or the time to a first exacerbation in patients with COPD who are at high risk for exacerbations.
(NEJM [June 5, 2014] 370:2201)
ENZALUTAMIDE SIGNIFICANTLY DECREASES THE RISK of radiographic progression and death in men with metastatic prostate cancer; the drug also delays the initiation of chemotherapy.
(NEJM [published online June 2014])
AS COMPARED WITH AN INSULIN PUMP, a wearable, automated, bihormonal, bionic pancreas improved mean glycemic levels, with less frequent hypoglycemic episodes, among both adults and adolescents with type 1 diabetes mellitus.
(NEJM [published online June 2014])
CARRIERS OF RARE MUTATIONS that disrupt APOC3 function may have a reduced risk of coronary heart disease.
(NEJM [July 3, 2014] 371:22)